#United States #Cranbury #Exosomes #Porton Advanced #Cosmetic Ingredients

Porton Advanced's Groundbreaking Achievement in Cosmetic Ingredients

Porton Advanced has made significant strides in the cosmetic industry with its proprietary stem cell-derived exosomes now officially recognized under the International Nomenclature of Cosmetic Ingredients (INCI). This landmark recognition marks a pivotal point in the company's journey toward becoming a key player in the global cosmetic market. The INCI system serves as a globally accepted standard, allowing for smooth entry into various countries and regions where the naming convention is already in use.

The INCI system, developed by the International Nomenclature Committee and promoted by the Personal Care Products Council, incorporates a wide array of over 16,000 cosmetic ingredients. It has been embraced by over 70 countries, including significant markets such as China, the United States, and the European Union. The listing of Porton Advanced's stem cell exosomes confirms compliance with international safety and quality standards, eliminating potential regulatory hurdles for brands eager to utilize these innovative ingredients.

Porton Advanced’s achievement is not merely a badge of honor; it signifies the company’s strategic maneuver to bolster its Contract Development and Manufacturing Organization (CDMO) services. With this accomplishment, the firm aims to diversify its offerings, extending into exosome raw materials and a broad range of cosmetic applications. This aligns seamlessly with the increasing global demand for innovative, science-based beauty products that elevate skincare routines and promote healthier skin.

In establishing a robust technological foundation, Porton Advanced employs a Good Manufacturing Practice (GMP)-compliant platform tailored to the cell and gene therapy sector. This infrastructure supports high standards of quality control and manufacturing processes, ensuring that their exosome products maintain superior purity, efficacy, and stability. The successful implementation of their exosome manufacturing platform has revealed several key features:

• - Flexible Cell Culture Systems: The facility supports multiple cell lines, such as HEK293, MSC, K562, and iPSC, catering to diverse research and commercial needs.
• - Scalable and Robust Processes: By scaling production from 2L to 50L bioreactors, Porton Advanced ensures a seamless transition from research and development to commercial-scale production.
• - High Yield: The final concentration of exosome products reaches an impressive ≥ 1E+11 particles/mL, showcasing efficient production techniques.
• - Rapid Delivery: The company can provide GMP-grade exosomes within one month, meeting the fast-paced demands of the beauty industry.
• - Stringent Quality Control Testing: Making use of comprehensive testing protocols ensures that every batch is consistent in terms of identity, purity, potency, and safety.

Looking ahead, Porton Advanced is committed to further exploring the applications of exosome technology, particularly within the realm of regenerative aesthetics. The organization plans to offer comprehensive solutions ranging from raw material customization to formulation development, enabling global partners to innovate within their product lines effectively.

About Porton Advanced

Porton Advanced Solutions operates as a subsidiary of Porton Pharma Solutions, a leading Contract Development and Manufacturing Organization (CDMO). With dual headquarters located in Cranbury, New Jersey, and Suzhou, China, Porton Advanced specializes in end-to-end CDMO solutions for Advanced Therapy Medicinal Products (ATMPs), which include plasmids, viral vectors, cell therapies, and nucleic acid therapies. The company’s extensive service offerings encompass everything from cell banking to process development and cGMP production, culminating in commercial viability. The expansive facilities, measuring 215,000 square feet, are outfitted with cutting-edge technology, housing 10 viral vector production lines, 12 cell therapy production suites, and numerous clean rooms designed to meet the growing demands of drug development and commercialization.